| 1. |
Fujikawa R, Tsuda M, The Functions and Phenotypes of Microglia in Alzheimer’s Disease, Cells, 2023.04. |
| 2. |
Makoto Tsuda, Microglia-Mediated Regulation of Neuropathic Pain: Molecular and Cellular Mechanisms, 10.1248/bpb.b19-00715 , 2019.12. |
| 3. |
Hidetoshi Tozaki-Saitoh, Makoto Tsuda, Microglia-neuron interactions in the models of neuropathic pain, Biochemical Pharmacology, 10.1016/j.bcp.2019.08.016, 2019.11, Chronic pain is a debilitating condition that often emerges as a clinical symptom of inflammatory diseases. It has therefore been widely accepted that the immune system critically contributes to the pathology of chronic pain. Microglia, a type of immune cell in the central nervous system, has attracted researchers’ attention because in rodent models of neuropathic pain that develop strong mechanical and thermal hypersensitivity, histologically activated microglia are seen in the dorsal horn of spinal cord. Several kinds of cytokines are generated by damaged peripheral neurons and contribute to microglial activation at the distal site of the injury where damaged neurons send their projections. Microglia are known as key players in the surveillance of the local environment in the central nervous system and have a significant role of circuit remodeling by physical contact to synapses. Key molecules for the pathology of neuropathic pain exist in the activated microglia, but the factors driving pain-inducible microglial activation remain unclear. Therefore, to find the key molecules inducing activation of spinal microglia and to figure out the precise mechanism of how microglia modulate neuronal circuits in the spinal cord to form chronic pain state is a critical step for developing effective treatment of neuropathic pain.. |
| 4. |
Makoto Tsuda, Microglia-mediated regulation of neuropathic pain
Molecular and cellular mechanisms, Biological and Pharmaceutical Bulletin, 10.1248/bpb.b19-00715, 2019.01, Pain is a defense system that responds rapidly to harmful internal and external stimuli through the somatosensory neuronal pathway. However, damage to the nervous system through cancer, diabetes, infection, autoimmune disease, chemotherapy or trauma often leads to neuropathic pain, a debilitating chronic pain condition. Neuropathic pain is not simply a temporal continuum of acute nociceptive signals from the periphery, but rather due to pathologically altered functions in the nervous system, which shift the net neuronal excitatory balance toward excitation. Although alterations were long thought to be a result of changes in neurons, but an increasing body of evidence over the past decades indicates the necessity and sufficiency of microglia, the tissue-resident macrophages of the spinal cord and brain, for nerve injury-induced malfunction of the nervous system. In this review article, I describe our current understanding of the molecular and cellular mechanisms underlying the role of microglia in the pathogenesis of neuropathic pain and discuss the therapeutic potential of microglia from recent advances in the development of new drugs targeting microglia.. |
| 5. |
Inoue K, Tsuda M, Microglia in neuropathic pain: cellular and molecular mechanisms and therapeutic potential., Nat Rev Neurosci, 10.1038/nrn.2018.2, 2018.03, Acute nociceptive pain is a key defence system that enables the detection of danger signals that threaten homeostasis and survival. However, chronic pain (such as the neuropathic pain that occurs after peripheral nerve injury) is not simply a consequence of the continuity of acute nociceptive signals but rather of maladaptive nervous system function. Over recent decades, studies have provided evidence for the necessity and sufficiency of microglia for the alterations in synaptic remodelling, connectivity and network function that underlie chronic pain and have shed light on the underlying molecular and cellular mechanisms. It is also becoming clear that microglia have active roles in brain regions important for the emotional and memory-related aspects of chronic pain. Recent advances in the development of new drugs targeting microglia and the establishment of new sources of human microglia-like cells may facilitate translation of these findings from bench to bedside.. |
| 6. |
Tsuda M, Astrocytes in the spinal dorsal horn and chronic itch., 10.1007/s12264-017-0129-y, 2018.02. |
| 7. |
Nishimura A, Sunggip C, Oda S, Numaga-Tomita T, Tsuda M, Nishida M, 5. Nishimura A, Sunggip C, Oda S, Numaga-Tomita T, Tsuda M, Nishida M, Pharmacol Ther, 10.1016/j.pharmthera.2017.06.010, 2017.12. |
| 8. |
TSUDA MAKOTO, P2 receptors, microglial cytokines and chemokines, and neuropathic pain, J Neurosci Res 95(6): 1319-1329, 2017.06. |
| 9. |
Sunggip C, Nishimura A, Shimoda K, Numaga-Tomita T, Tsuda M, Nishida M, Purinergic P2Y6 receptors: A new therapeutic target of age-dependent hypertension., Pharmacol Res, 10.1016/j.phrs.2017.03.013, 2017.06. |
| 10. |
TSUDA MAKOTO, Spinal dorsal horn astrocytes: new players in chronic itch, Allergol Int 66: 31-35, 2017.01. |
| 11. |
TSUDA MAKOTO et al., Neuron-microglia interaction by purinergic signaling in neuropathic pain following neurodegeneration, Neuropharmacology, 104:76-81, 2016.05. |
| 12. |
Masuda T et al., Transcriptional regulation in microglia and neuropathic pain, Pain Manag. 6(2): 91-94, 2016.04. |
| 13. |
TSUDA MAKOTO et al., Microglial regulation of neuropathic pain, J Pharmacol Sci, 2013.10. |
| 14. |
TSUDA MAKOTO, Masuda Takahiro, Hidetoshi Saitoh, Kazuhide Inoue, Microglial regulation of neuropathic pain, J Pharmacol Sci, 2013.02. |
| 15. |
TSUDA MAKOTO, Beggs S, Salter MW, Kazuhide Inoue, Microglia and intractable chronic pain, Glia, 2013.01. |
| 16. |
Kazuhide Inoue, TSUDA MAKOTO, P2X4 receptors of microglia in neuropathic pain, CNS Neurol Disord Drug Targets, 2012.09. |
| 17. |
Inoue K, Tsuda M., Purinergic systems, neuropathic pain and the role of microglia., Exp Neurol., 2012.04. |
| 18. |
Tsuda M, Tozaki-Saitoh H, Inoue K., Purinergic system, microglia and neuropathic pain., Curr Opin Pharmacol., 2012.02. |
| 19. |
Tozaki-Saitoh H, Tsuda M, Inoue K, Role of purinergic receptors in CNS function and neuroprotection., Adv Pharmacol, 2011.09. |
| 20. |
Tsuda M, Tozaki-Saitoh H, Inoue K, Platelet-activating factor and pain., Biol Pharm Bull., 2011.07. |
| 21. |
Inoue K, Koizumi S, Kataoka A, Tozaki-Saitoh H, Tsuda M, P2Y6-evoked microglial phagocytosis, Int Rev Neurobiol, 2010.07. |
| 22. |
Tsuda M, Tozaki-Saitoh H, Inoue K, Pain and purinergic signaling. , Brain Res Rev, 2010.05. |
| 23. |
Inoue K, Tsuda M, Microglia and neuropathic pain., Glia, 2009.11. |
| 24. |
Inoue K, Koizumi S, Tsuda M, The role of nucleotides in the neuron–glia communication responsible for the brain functions, J Neurochem 102: 1447–1458 (2007), 2007.09. |
| 25. |
Kazuhide Inoue, Makoto Tsuda, Hidetoshi Tozaki-Saitoh, Modification of neuropathic pain sensation through microglial ATP receptors, Purinergic Signalling, 3: 311-316 (2007), 2007.09. |
| 26. |
Inoue K, Tsuda M, Koizumi S., ATP receptors in pain sensation: Involvement of spinal microglia and P2X4 receptors., Purinergic Signalling, 1, 95-100 (2005)., 2005.04. |
| 27. |
Tsuda M, Inoue K, Salter MW., Neuropathic pain and spinal microglia: a big problem from molecules in "small" glia., Trends Neurosci. 2005 Feb;28(2):101-7., 2005.02. |
| 28. |
Inoue K, Tsuda M, Koizumi S., ATP- and adenosine-mediated signaling in the central nervous system: chronic pain and microglia: involvement of the ATP receptor P2X4., J Pharmacol Sci. 2004 Feb;94(2):112-4., 2004.02. |
| 29. |
Inoue K, Koizumi S, Ueno S, Kita A, Tsuda M., The functions of ATP receptors in the synaptic transmission in the hippocampus., Prog Brain Res. 1999;120:193-206., 1999.11. |
| 30. |
Tsuda M, Shimizu N, Suzuki T., Contribution of glutamate receptors to benzodiazepine withdrawal signs., Jpn J Pharmacol. 1999 Sep;81(1):1-6., 1999.09. |
